Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net Loss	$ (48,976,896)	$ (6,864,676)
Adjustments to reconcile net loss to cash used in operating activities
Change in fair value of warrant liability	(9,327,326)
Stock issued in lieu of cash for services	33,467
Stock-based compensation	12,597,001	1,977,155
Accrued interest		156,619
Amortization of debt discount		288,631
Inducement expense	1,125,291	802,109
Amortization of right-of-use operating lease asset	24,969
Depreciation expense	13,310
Impairment of intangible assets and goodwill	38,678,918
Amortization of intangible assets	643,333	120,872
Non-cash income tax benefit	(7,454,805)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	826,837	(636,497)
Accounts payable, and accrued liabilities	383,199	267,002
Right-of-use operating lease liability	(24,969)
Net cash used in operating activities	(11,457,671)	(3,888,785)
Cash flows from investing activities:
Purchase of license agreements	(675,000)	(44,143)
Cash accretive acquisition of MagicMed	3,055,328
Equipment purchases	(189,719)
Net cash (used in) provided by investing activities	2,190,609	(44,143)
Cash flows from financing activities:
Proceeds from convertible notes payable		50,000
Proceeds from note payable, net of offering costs		1,812,410
Offering and reverse merger proceeds		3,372,500
Proceeds from sales of common stock and warrants, net	21,614,488	488,000
Proceeds from exercise of cash warrants	3,285,171
Repayment of note payable		(191,640)
Net cash provided by financing activities	24,899,659	5,531,270
Effect of foreign exchange rate on cash	144,942	(63,596)
Net increase in cash	15,777,539	1,534,746
Cash – beginning of the year	1,578,460	43,714
Cash – end of the year	17,355,999	1,578,460
Supplemental disclosure of non-cash transactions:
Right-of-use assets obtained in exchange for lease liabilities	201,653
Supplemental non-cash financing activities:
Issuance of Common Stock pursuant to MagicMed amalgamation	39,042,282
Deferred tax liability incurred due to MagicMed amalgamation	9,061,927
Conversion of preferred stock to common stock	32,754
Fair value of warrants issued	9,981,000
Beneficial conversion feature issued with note payable		17,851
Warrants issued in conjunction with notes payable		32,149
Common stock issued for accounts payable		756,523
Common stock issued in conjunction with note payable modification		101,713
Conversion of related party advances and notes payable into common stock		679,569
Common stock issued for skincare license		1,900,546
Supplemental cash financing activities:
Cash paid for interest	$ 10,316